Tag Archives: ENCO

Companies in the Biotech industry to watch: PWRM, ABCO, and ENCO

Power3 Medical Products, Inc. – (OTC.BB: PWRM) strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. The Company will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

PWRM is a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. This dynamic team utilizes proteomics in the discovery of protein biomarkers, drug pathways, and mechanisms of disease.

Skymark Research, a leading provider of small- and micro-cap independent investment research, recently initiated coverage on PWRM. Also on July 12 in Honolulu, Hawaii Power 3 will be presenting four abstracts to this annual meeting of the International Congress of Alzheimer’s Disease. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro® AD biomarkers and blood test for Alzheimer’s disease. The four studies to be presented involve a total of 154 Alzheimer’s disease patients and 91 Parkinson’s disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

For more information visit www.power3medical.com.

—————————————————–

The Advisory Board Company – (NasdaqGS: ABCO) provides best practices research, analysis, executive education and leadership development, business intelligence software tools, and installation support services primarily to the health care industry. Its programs focus on business strategy, operations, and general management issues.

Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, recently initiated coverage on ABCO.

The Advisory Board strides to proceeds in the belief that organizations in certain sectors—health care, education, and government among them—have a charter above commerce, but preserving this higher calling requires an unyielding insistence on improvement. Their mission is to surface and secure economies of intellect on behalf of member organizations—discerning “True North,” communicating these insights and best practices with clarity, and providing innovative services such that our members can set compass and elevate performance accordingly.

ABCO proceeds in the belief that organizations in certain sectors—health care, education, and government among them—have a charter above commerce, but preserving this higher calling requires an unyielding insistence on improvement. Our mission is to surface and secure economies of intellect on behalf of member organizations—discerning “True North,” communicating these insights and best practices with clarity, and providing innovative services such that our members can set compass and elevate performance accordingly.

Keep researching at http://www.advisoryboardcompany.com

——————————————————

Encorium Group, Inc. – (NasdaqCM: ENCO) designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe. The company’s clinical research and development services supporting Phase I through Phase IV clinical trials include data management, such as CRF review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; and biostatistics for the use of professionals to develop and review protocols, design analysis plans, and report formats in various phases of drug development.

ENCO announced that the company filed a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) for a proposed rights offering to its existing stockholders. The proposed rights offering would be made through the distribution of subscription rights to purchase up to $10 million of the company’s shares of common stock, par value $0.001 per share, on the terms and conditions and at a price determined by a special committee of the company’s board of directors.

Chief Executive Officer, Dr. Kai Lindevall said, “The proposed rights offering is designed to provide additional working capital and liquidity to the Company by giving each stockholder a chance to buy additional shares and the opportunity to avoid dilution of their ownership interests.”

Members of the company are just returning from the annual European Vaccine Forum in Barcelona, which took place from June 21-23

Share This: